3/7/2011

Ista Pharmaceuticals sent a petition asking the FDA to reject any generic version's application for the withdrawn twice-daily eye medicine Xibrom that uses the original labeling. Ista said any generic's label should include a reference to the option of the once-daily dose.

Full Story:
Reuters

Related Summaries